Leerink Partnrs Forecasts Reduced Earnings for ICON Public

ICON Public Limited (NASDAQ:ICLR) – Equities research analysts at Leerink Partnrs reduced their FY2025 earnings per share estimates for ICON Public in a report issued on Tuesday, January 14th. Leerink Partnrs analyst M. Cherny now expects that the medical research company will post earnings per share of $13.44 for the year, down from their previous estimate of $13.98. The consensus estimate for ICON Public’s current full-year earnings is $13.41 per share. Leerink Partnrs also issued estimates for ICON Public’s FY2026 earnings at $15.67 EPS and FY2027 earnings at $17.73 EPS.

ICON Public (NASDAQ:ICLR) last announced its quarterly earnings data on Wednesday, October 23rd. The medical research company reported $3.35 earnings per share for the quarter, missing analysts’ consensus estimates of $3.72 by ($0.37). The company had revenue of $2.03 billion for the quarter, compared to the consensus estimate of $2.13 billion. ICON Public had a net margin of 9.00% and a return on equity of 11.91%. The company’s quarterly revenue was down 1.2% compared to the same quarter last year. During the same quarter in the previous year, the business earned $3.10 EPS.

ICLR has been the subject of several other reports. Barclays lowered their target price on ICON Public from $330.00 to $275.00 and set an “overweight” rating for the company in a report on Friday, October 25th. TD Cowen dropped their target price on shares of ICON Public from $369.00 to $285.00 and set a “buy” rating on the stock in a report on Friday, October 25th. Citigroup reduced their price target on shares of ICON Public from $300.00 to $290.00 and set a “buy” rating for the company in a report on Monday, January 6th. Redburn Atlantic began coverage on shares of ICON Public in a research note on Monday, October 14th. They set a “neutral” rating and a $311.00 price objective on the stock. Finally, Royal Bank of Canada reissued an “outperform” rating and issued a $263.00 price objective on shares of ICON Public in a research note on Wednesday. Four investment analysts have rated the stock with a hold rating, eleven have given a buy rating and one has assigned a strong buy rating to the company’s stock. According to data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $287.00.

ICON Public Stock Down 2.2 %

Shares of NASDAQ ICLR opened at $198.11 on Friday. The stock has a 50 day moving average price of $209.71 and a 200 day moving average price of $267.88. The firm has a market capitalization of $16.34 billion, a price-to-earnings ratio of 22.09, a PEG ratio of 1.59 and a beta of 1.20. ICON Public has a 52-week low of $183.38 and a 52-week high of $347.72. The company has a debt-to-equity ratio of 0.35, a quick ratio of 1.34 and a current ratio of 1.34.

Institutional Investors Weigh In On ICON Public

A number of large investors have recently modified their holdings of the business. EverSource Wealth Advisors LLC boosted its stake in ICON Public by 39.2% in the 2nd quarter. EverSource Wealth Advisors LLC now owns 394 shares of the medical research company’s stock worth $129,000 after purchasing an additional 111 shares in the last quarter. Sara Bay Financial acquired a new stake in shares of ICON Public during the third quarter worth $1,143,000. Whittier Trust Co. lifted its stake in shares of ICON Public by 12.3% during the third quarter. Whittier Trust Co. now owns 4,020 shares of the medical research company’s stock worth $1,155,000 after buying an additional 441 shares during the period. Whittier Trust Co. of Nevada Inc. grew its holdings in shares of ICON Public by 23.1% during the third quarter. Whittier Trust Co. of Nevada Inc. now owns 511 shares of the medical research company’s stock valued at $147,000 after buying an additional 96 shares during the last quarter. Finally, Arkadios Wealth Advisors raised its stake in ICON Public by 5.0% in the 3rd quarter. Arkadios Wealth Advisors now owns 1,293 shares of the medical research company’s stock worth $371,000 after acquiring an additional 62 shares during the last quarter. Hedge funds and other institutional investors own 95.61% of the company’s stock.

ICON Public Company Profile

ICON Public Limited Company, a clinical research organization, provides outsourced development and commercialization services in Ireland, rest of Europe, the United States, and internationally. The company specializes in the strategic development, management, and analysis of programs that support various stages of the clinical development process from compound selection to Phase I-IV clinical studies.